Last 332.50 GBp
Change Today 0.00 / 0.00%
Volume 0.0
EHP On Other Exchanges
Symbol
Exchange
London
Berlin
OTC US
As of 3:00 AM 07/10/14 All times are local (Market data is delayed by at least 15 minutes).

epistem holdings plc (EHP) Snapshot

Open
332.50 GBp
Previous Close
332.50 GBp
Day High
332.50 GBp
Day Low
332.50 GBp
52 Week High
08/1/13 - 582.50 GBp
52 Week Low
10/8/13 - 320.00 GBp
Market Cap
33.3M
Average Volume 10 Days
22.1K
EPS TTM
-0.16 GBp
Shares Outstanding
10.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for EPISTEM HOLDINGS PLC (EHP)

Related News

No related news articles were found.

epistem holdings plc (EHP) Related Businessweek News

No Related Businessweek News Found

epistem holdings plc (EHP) Details

Epistem Holdings Plc operates as a biotechnology and personalized medicine company commercializing its expertise in epithelial stem cells and infectious disease. The company provides pre-clinical testing, pharmacogenomic biomarker and diagnostic services to the biotechnology and pharmaceutical industries in the United Kingdom and Europe, the United States, and Asia; and develops proprietary molecular tools for the diagnosis of infectious diseases across the world. It operates in three divisions: Preclinical Research Services, Personalised Medicine, and Novel Therapies. The Preclinical Research Services division provides preclinical efficacy testing, immunohistochemistry services, and cell biology expertise in the areas of oncology, oncology supportive care, inflammatory bowel disease, rheumatoid arthritis, and dermatology. The Personalized Medicine division offers sensitive molecular measures of biological processes that enhance precision in drug development, patient stratification and disease treatment. This division discovers, develops, and translates biomarkers for clinical drug development; and offers Genedrive, a molecular diagnostic tool used in bacterial, viral, fungal, and somatic mutational disease identification. The Novel Therapies division is involved in discovering regulators of adult epithelial stem cells and tissues; and developing protein therapeutics that control cell production in the areas of oncology, oncology supportive care, and epithelial diseases. The company was founded in 2000 and is based in Manchester, the United Kingdom.

67 Employees
Last Reported Date: 11/26/13
Founded in 2000

epistem holdings plc (EHP) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: 300.0K GBP
Co-Founder, Managing Director of Contract Res...
Total Annual Compensation: 104.1K GBP
Chief Financial Officer, Finance Director, Co...
Total Annual Compensation: 130.0K GBP
Compensation as of Fiscal Year 2013.

epistem holdings plc (EHP) Key Developments

Epistem Announces Installation of UK's First Bruker Xtreme Imaging System

Epistem Holdings Plc announced the successful installation of the Bruker Xtreme Imaging System within its contract research services division. This is the first such machine in the UK and will enable Epistem to expand both the range and throughput of its imaging services, particularly in the field of oncology. The Bruker Xtreme provides high sensitivity luminescence, fluorescence, radio-isotopic and radiographic (X-ray) imaging. Combined with Epistem's specialized pre-clinical knowledge this increases the range of assays the company can provide to its clients as well as their ability to identify new targets for cancer therapy.

EpiStem Holdings Plc Reports Unaudited Consolidated Earnings Results for the Six Months Ended December 31, 2013

EpiStem Holdings Plc reported unaudited consolidated earnings results for the six months ended December 31, 2013. For the period, the company reported revenue of £2,544,000 against £2,751,000 a year ago. Revenue and other income was £2,888,000 against £3,051,000 a year ago. Operating loss was £703,000 against £344,000 a year ago. Loss on ordinary activities before taxation was £730,000 against £329,000 a year ago. Total comprehensive loss for the financial period was £584,000 against £249,000 a year ago. Basic and diluted loss per share was 6.0 pence against 4.8 pence a year ago. Net cash outflow from operations were £645,000 against £924,000 a year ago. Net cash outflow from operating activities were £27,000 against net cash inflow from operating activities of £10,000 a year ago. Acquisition of fixed assets was £706,000 against £626,000 a year ago.

Epistem Announces Opening of US Laboratory

Epistem Holdings Plc announced that it has opened a US laboratory based in Baltimore, Maryland. The laboratory will support the expansion of Epistem's contract research division within the US.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EHP:LN 332.50 GBp 0.00

EHP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for EHP.
View Industry Companies
 

Industry Analysis

EHP

Industry Average

Valuation EHP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.5x
Price/Book 2.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EPISTEM HOLDINGS PLC, please visit www.epistem.co.uk. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.